Narrow search
Showing 1 - 9 of 9
Cover Image
Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland
Lebioda, Andrea; Gasche, David; Dippel, Franz-Werner; … - In: Health Economics Review 4 (2014) 31, pp. 1-14
Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz … assess the additional benefit of the new drug. However, the Institute for Quality and Efficiency in Health Care (IQWiG …
Persistent link: https://www.econbiz.de/10011599783
Cover Image
Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: Whenever IQWiG and Federal Joint Committee dis...
Dintsios, C. M.; Worm, F.; Ruof, Jörg; Herpers, M. - In: Health Economics Review 9 (2019) 35, pp. 1-15
(FJC) to the HTA body (IQWiG) and their agreement with FJC decisions and to identify potential additional decisive factors … to descriptive statistics, differences between IQWiG and FJC were tested and explored by agreement statistics (Cohen … of the appropriate comparative therapy had a high influence on FJC's appraisals deviating from IQWiG's addenda …
Persistent link: https://www.econbiz.de/10014489869
Cover Image
Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland
Lebioda, Andrea; Gasche, David; Dippel, Franz-Werner; … - In: Health economics review 4 (2014) 31, pp. 1-14
Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz … assess the additional benefit of the new drug. However, the Institute for Quality and Efficiency in Health Care (IQWiG …
Persistent link: https://www.econbiz.de/10010526947
Cover Image
Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany : whenever IQWiG and Federal Joint Committee di...
Dintsios, C. M.; Worm, F.; Ruof, Jörg; Herpers, M. - In: Health economics review 9 (2019) 35, pp. 1-15
(FJC) to the HTA body (IQWiG) and their agreement with FJC decisions and to identify potential additional decisive factors … to descriptive statistics, differences between IQWiG and FJC were tested and explored by agreement statistics (Cohen … of the appropriate comparative therapy had a high influence on FJC’s appraisals deviating from IQWiG’s addenda …
Persistent link: https://www.econbiz.de/10012162522
Cover Image
Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland
Lebioda, Andrea; Gasche, David; Dippel, Franz-Werner; … - In: Health Economics Review 4 (2014) 1, pp. 1-14
Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz … assess the additional benefit of the new drug. However, the Institute for Quality and Efficiency in Health Care (IQWiG …
Persistent link: https://www.econbiz.de/10011151927
Cover Image
Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany
Herpers, Matthias; Dintsios, Charalabos-Markos - In: The European journal of health economics : HEPAC ; … 20 (2019) 1, pp. 45-57
Persistent link: https://www.econbiz.de/10011998030
Cover Image
Market withdrawals' of medicines in Germany after AMNOG: A comparison of HTA ratings and clinical guideline recommendations
Staab, Thomas R.; Walter, Miriam; Mariotti Nesurini, Sonja - In: Health Economics Review 8 (2018) 23, pp. 1-11
Background: According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of … appraisals of medicines that were withdrawn from the German market since the introduction of AMNOG in 2011. Methods: Medications …-BA (average 'no additional benefit' rating for all AMNOG products: 47%). Of the 22 medicines, 15 (68%) were recommended by at …
Persistent link: https://www.econbiz.de/10012010779
Cover Image
"Market withdrawals" of medicines in Germany after AMNOG : a comparison of HTA ratings and clinical guideline recommendations
Staab, Thomas R.; Walter, Miriam; Mariotti Nesurini, Sonja - In: Health economics review 8 (2018) 23, pp. 1-11
Background: According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of … appraisals of medicines that were withdrawn from the German market since the introduction of AMNOG in 2011. Methods: Medications …-BA (average ‘no additional benefit’ rating for all AMNOG products: 47%). Of the 22 medicines, 15 (68%) were recommended by at …
Persistent link: https://www.econbiz.de/10011942830
Cover Image
Four years of early benefit assessment of new drugs in Germany : a qualitative study on methodological requirements for quality of life data
Blome, Christine; Augustin, Matthias; Metin, Hidayet; … - In: The European journal of health economics : HEPAC ; … 18 (2017) 2, pp. 181-193
Persistent link: https://www.econbiz.de/10011867761